ArticleFrontiers in molecular biosciences2026
Unlocking personalized endometrial cancer treatment: the critical role of the BBIRE biobank in sample collection and distribution.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endometrial cancer (EC) is the most common gynecological malignancy and the sixth most common cancer in women. Although it primarily affects women around or after menopause, an increasing number of cases are now being found in women of reproductive age. This shift highlights the need for fertility-sparing treatments and research. Methods: The tumor biobank of the Regina Elena National Cancer Institute (BBIRE) has played a central role in EC research by simplifying the collection and distribution of high-quality samples linked to clinical data. BBIRE follows strict protocols and uses secure databases to protect patient privacy, meet regulations, and keep clinical information accurate. These steps help maintain sample quality and reduce errors before analysis. Results: This research highlights the importance of the BBIRE-tissue processing group in the coordinated management of 545 gynecological tumor samples, comprising 321 EC samples, underscoring its importance as a crucial instrument for translational research. The biobank supports a complete research process, from patient enrollment to molecular data analysis. Its flexible, standardized structure helps ensure reliable results in different research settings. Discussion: As a gynecologic oncology resource, BBIRE facilitates large-scale studies and collaboration among team researchers. This support is essential for identifying new biomarkers, tailoring treatments, and advancing precision medicine. The development of personalized care and improved outcomes for women with EC can be accelerated when work is performed collaboratively by surgeons, biobanks, and researchers. Statement of Significance: The BBIRE Biobank is a game changer in cancer research that enables the integration of annotated samples, multiomics data, and organoid models to identify molecular drivers and accelerate personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.